Cost of Goods Sold (Annual)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

Bora Pharmaceuticals Co., Ltd. - Sponsored ADR (BORAY) had Cost of Goods Sold of 358.27M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	610.35M
Net Income	95.70M
Cost of Goods Sold	358.27M
Gross Profit	252.08M
Operating Expenses	504.63M
Operating Income	105.72M
Non-Operating Income/Expense	63.70M
Pre-Tax Income	169.42M
Normalized Pre-Tax Income	169.42M
Income after Taxes	142.78M
Income from Continuous Operations	142.78M
Consolidated Net Income/Loss	97.78M
Normalized Income after Taxes	142.78M
EBIT	105.72M
EBITDA	140.60M
Weighted-Average Shares Outstanding (Basic)	623.78M
Weighted-Average Shares Outstanding (Diluted)	678.68M
Earnings per Share (EPS) (Basic)	0.15
Earnings per Share (EPS) (Diluted)	0.15
Balance Sheet Financials
Current Assets	620.74M
Property, Plant, and Equipment	334.91M
Long-Term Assets	814.59M
Total Assets	1.44B
Current Liabilities	427.60M
Long-Term Debt	378.66M
Long-Term Liabilities	446.87M
Total Liabilities	874.47M
Common Equity	560.86M
Tangible Shareholders Equity	360.41M
Shareholders Equity	560.86M
Common Shares Outstanding	634.94M
Cash Flow Statement Financials
Cash Flow from Operating Activities	144.57M
Cash Flow from Investing Activities	-108.49M
Cash Flow from Financial Activities	-44.20M
Beginning Cash	187.12M
End Cash	162.97M
Increase/Decrease in Cash	-24.15M
Stock-Based Compensation	2.52M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.45
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.40
Debt to Equity Ratio	1.00
Gross Margin	41.30%
Operating Margin	17.32%
EBIT Margin	17.32%
EBITDA Margin	23.04%
Pre-Tax Profit Margin	27.76%
Profit Margin	15.68%
Free Cash Flow	123.30M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.43
Inventory Turnover	3.27
Receiveable Turnover	2.08
Days Sales in Receivables	175.35
Return on Equity	25.46%
Return on Tangible Equity	39.62%
Return on Assets	9.95%
Return on Investments	15.20%
Book Value Per Share	0.88
Free Cash Flow per Share	0.18
Operating Cash Flow per Share	0.21

Data from Zacks Investment Research, Inc.